Veru (VERU) Capital Expenditures (2010 - 2024)

Veru (VERU) posted quarterly Capital Expenditures of $1083.0 for Q4 2024, down 98.28% quarter-over-quarter from $63036.0 in Q3 2024.

Veru (VERU) Capital Expenditures (2010 - 2024) Analysis & Trends

Veru (VERU) has reported Capital Expenditures for 15 consecutive years, with $1083.0 the latest figure, recorded in Q4 2024.

In Q4 2024, Capital Expenditures changed N/A year-over-year to $1083.0; the TTM figure through Sep 2025 stood at $1083.0 (down 99.32% YoY), while the FY2025 annual figure was $1083.0, down 99.32% from the prior year.
Capital Expenditures slipped to $1083.0 in Q4 2024 per VERU's latest filing, from $63036.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $302209.0 in Q4 2021 and bottomed at $1083.0 in Q4 2024.
Historically, Capital Expenditures has averaged $106250.5 across 5 years, with a median of $63036.0 in 2024.
Annual changes were most pronounced in 2020 — Capital Expenditures soared 5004.5% — and 2021, when it tumbled 85.0%.
Veru's Capital Expenditures stood at $7186.0 in 2020, then soared by 4105.52% to $302209.0 in 2021, then retreated by 5.51% to $285565.0 in 2022, then dropped by 25.46% to $212874.0 in 2023, then sank by 99.49% to $1083.0 in 2024.
Business Quant data shows VERU's Capital Expenditures at $1083.0 in Q4 2024, $63036.0 in Q3 2024, and $54630.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Veru	60.85 Mn	35.06 Mn	-	-

Download Data